Bile acids shaped by gut microbes can influence inflammation and metabolism, so understanding these pathways could lead to new biomarkers or treatments relevant to people with IBD.

New targeted-delivery research could lead to treatments that reduce gut inflammation while also shifting the microbiome — both relevant to IBD management. However, this report is preclinical and does not mean the therapy...

Finding neutralising anti-IL-10 antibodies in a subset of children with IBD may help explain why some patients have more severe, treatment‑resistant disease and points to a potential biomarker for risk stratification.

Shared gut microbiome shifts across autoimmune diseases could suggest common microbial factors relevant to immune regulation and might eventually inform diagnostics or therapies relevant to people with IBD.

Pouch-related fistula is a serious late complication after IPAA. The study suggests people with UC who undergo IPAA may have higher fistula risk than patients with FAP, and that inflammatory pouch disease (like...

The study suggests anti-TNF failure in Crohn's may be driven by pre-existing cytokine interaction networks and loss of regulatory feedback, which could help explain why some patients don't respond to TNF-blocking...

The study highlights GM‑CSF as a spatial regulator of myeloid–lymphoid interactions in ulcerated ileal tissue, which may help researchers and clinicians understand mechanisms that drive inflammation and epithelial injury...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis and Research and clinical trials. The original article is from Journal of Visualized Experiments.

Based on the title and source metadata, this appears to be a regulatory update related to Mirikizumab, IL-23 inhibitor, and Medications. The original article is from DailyMed.

Cure8 indexed source-provided abstract text from National Center for Health Statistics (U.S.), but this record did not meet the threshold for a full Cure8 brief. It is tagged for Inflammatory bowel disease and Research...

Based on the title and source metadata, this appears to be a video related to Inflammatory bowel disease and Community and awareness. The original article is from hmpgloballearningnetwork.com.

Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...

Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Infliximab, and Azathioprine.

Back-to-school planning can reduce emergencies and missed care for students with chronic conditions, including Crohn’s disease. Preparing plans, communicating with school or campus staff, and knowing where to get care...

AI could help make IBD assessments (endoscopy, histology, imaging, biomarkers) more objective and faster, which may improve monitoring, treatment selection, and early detection of complications for people with Crohn’s...

Shows that in Crohn’s disease, inflammatory changes in circulating monocytes appear before they enter the gut, which could help explain persistent intestinal macrophage dysfunction and may guide future biomarker or...

If PALI-2108 proves safe and effective in Phase 2 trials, it could add a new oral treatment option for people with ulcerative colitis and Crohn’s disease. Early Phase 1 signals and a funded Phase 2 program mean the...

This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...

Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from t.co.

The study connects common dietary patterns to self‑reported IBD activity and quality of life, suggesting diet may be linked to symptom burden for people with Crohn’s disease and UC/IBDU.

Researchers used genetics plus single-cell sequencing and ELISA to prioritize plasma protein ratios that may causally relate to ulcerative colitis. If validated in larger studies, such biomarkers could help with...

If you have IBD, the mouth and gums may be part of shared inflammatory pathways with your gut. Periodontitis is associated with higher odds of having IBD in cross-sectional studies and has a modest link to later...

Identifies factors that may raise the chance of developing pouchitis after IPAA — useful for patients considering or recovering from proctocolectomy and for clinicians planning perioperative care or monitoring.

Cure8 indexed source-provided abstract text from The Journal of Dermatology, but this record did not meet the threshold for a full Cure8 brief. It is tagged for Crohn's disease, Inflammatory bowel disease, and...

People with IBD and other immune-mediated inflammatory diseases may be at risk for lasting symptoms after COVID-19, and those symptoms were associated with worse quality of life in this study. Awareness can help...

This study aims to identify which clinical or biological factors predict treatment response and serious complications in children with newly diagnosed IBD — information that could help tailor care for pediatric patients...

Hospitalized patients with acute severe ulcerative colitis face high short-term risk of colectomy and need effective rescue strategies; this trial tests a personalized, adaptive approach to inpatient medical therapy and...

Long-term extension trials help show whether a drug’s benefits and safety persist over time. For people with Crohn’s disease, this study focuses on maintaining endoscopic improvement and clinical remission with...

Cure8 could only read part of this source from grafa.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.

This news matters because SL-325 targets the TL1A/DR3 pathway, a novel immune target being tested for Crohn’s disease and UC; early Phase 1 data suggest a tolerable profile and prolonged target blockade that could affect...

This study links blood gene signatures shared between Parkinson’s disease and intestinal inflammation to astrocyte-associated molecular changes in the brain, identifying HSP90AA1 as a candidate stress-responsive hub.

Chronic visceral pain is common in people with IBD and IBS and current treatments often do not address nerve pathways that drive pain. Research aiming to target pain-signalling could eventually lead to more effective,...

AI models that combine CTE/MRE imaging with clinical and molecular data could improve objective classification of small-bowel Crohn's disease and help predict which patients are likely to respond to medical therapy...

Perianal fistulas are a serious complication of Crohn’s disease and can be hard to treat. This trial tested a novel extracellular-vesicle therapy (ExoFlo) delivered locally as a potential new option, so patients with...

Finding a blood biomarker that predicts histologic remission could make disease monitoring less invasive and help guide when colonoscopy is needed for people with ulcerative colitis.

This pilot trial explores a non-drug neuromodulation approach (auricular vagus nerve stimulation) that might influence brain–gut interactions, stress, fatigue, and quality of life in people with IBD in remission....

The trial tests two low-cost adjuncts — a Lactobacillus probiotic and a multi–trace-element supplement — added to biologic-based standard care to see if they help maintain remission in ulcerative colitis. If effective,...

Early clinical data suggest SL-325 engages its target (TL1A) with a favorable safety signal, and a Phase 2b trial in Crohn’s disease is planned — meaning this could become a new treatment option in the future if later...

Faecal calprotectin appears to be the best non‑invasive test among those studied for distinguishing UC from Crohn’s disease and for reflecting mucosal inflammation. Simpler blood‑based scores may help gauge systemic...

Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Natalizumab, and Biosimilars.

Smart, stimuli-responsive nanocarriers could one day allow IBD treatments to act more precisely in the gut and limit side effects; that may matter to people hoping for better-targeted therapies or fewer systemic...

If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...

This study links population-level IBD epidemiology to gut microbiome changes and proposes a microbial risk score that might help detect or surveil IBD patterns. That could inform future biomarker development or...

Cure8 found this source from Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Stricture, and Complications. Open the original article for the full details.

This review suggests Aloe vera polysaccharides could support gut barrier repair, microbiome balance, and immune regulation—mechanisms relevant to IBD inflammation and healing. However, evidence is mainly preclinical and...

ILCs help regulate mucosal immunity and their imbalance is linked to intestinal inflammation; understanding them may point to new biomarkers and future therapies for IBD. Clinicians and researchers may find insights...

Nanotechnology approaches aim to improve how cytokine-targeting therapies are delivered in IBD, which could reduce systemic exposure and immunogenicity and increase local effectiveness.